You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 9,532,949


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,532,949
Title:Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers
Abstract: In one embodiment, the invention provides a new design of nanocarrier compositions that release their therapeutic load specifically at intraperitoneal cancers\' site. These nanocarriers are administered intraperitoneally and comprise a plurality of porous nanoparticulates that (a) are loaded with one or more pharmaceutically-active agents alone or in combination with imaging agents thus providing a theranostic value and (b) that are encapsulated by and that support a lipid bilayer which is disrupted upon contact with a reactive oxygen species generated within the environment of the cancer. In other embodiments, the invention provides methods of treatment and pharmaceutical compositions comprising nanocarriers as described herein.
Inventor(s): Zeineldin; Reema (Shrewsbury, MA)
Assignee: STC.UNM (Albuquerque, NM)
Application Number:14/233,527
Patent Claims:1. A method of treating a subject who suffers from a cancer, the method comprising intraperitoneally administering to the subject a pharmaceutically effective amount of a nanocarrier composition, comprising a plurality of porous nanoparticulates that are loaded with one or more pharmaceutically active anticancer agents and are encapsulated by and support a lipid bilayer which is disrupted upon contact with a reactive oxygen species, wherein the lipid bilayer comprises 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC).

2. The method of claim 1, wherein: (a) the subject suffers from peritoneal cancer and the composition comprising nanocarriers is administered intraperitoneally to the subject's uterus; (b) the nanoparticulates are selected from the group consisting of silica nanoparticles, a biodegradable polymer, a sol-gel, a metal-based nanoparticle and an oxide-based nanoparticle; (c) subsequent to administration, the lipid bilayer of said nanocarriers is disrupted upon contact with a reactive oxygen species (ROS) selected from the group consisting of ozone (O.sub.3), hydrogen peroxide, hypochlorite ion, hydroxyl radical, superoxide anion (O.sub.2.sup.-), and peroxynitrite; and (d) the nanocarriers' one or more anti-cancer agents are selected from the group consisting of doxorubicin, melphalan, bevacizumab, dactinomycin, cyclophosphamide, amifostine, etoposide, gemcitabine, altretamine, topotecan, a taxane, a platinum based chemotherapeutic agent, and combinations thereof.

3. The method of claim 1, wherein the subject is co-administered one or more additional anti-cancer agents or anti-cancer treatments along with the nanocarrier composition.

4. The method of claim 3, wherein the one or more additional anti-cancer agents or anti-cancer treatments and nanocarrier composition are administered concomitantly to the subject.

5. The method according to claim 1 wherein said composition is administered directly into the cancer/tumor.

6. The method of claim 1, wherein the reactive oxygen species is selected from the group consisting of ozone (O.sub.3), hydrogen peroxide, hypochlorite ion, hydroxyl radical, superoxide anion (O.sub.2.sup.-), and peroxynitrite.

7. The method of claim 1, wherein the lipid bilayer further comprises one or more lipids selected from the group consisting of phospholipids, cholesterol, a phosphatidyl-choline, a phosphatidyl-serine, a phosphatidyl-diethanolamine, a phosphatidylinosite, a sphingolipid, and an ethoxylated sterol, and mixtures thereof.

8. The method of claim 1, wherein the lipid bilayer further comprises one or more phospholipids selected from the group consisting of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), egg phosphatidyl-choline (PC), a lipid mixture comprising between about 40 to 60% by weight of one or more unsaturated phosphatidyl-choline, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) [16:0], 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) [18:0], 1,2-dioleoyl-sn-glycero-3-phosphocholine, and combinations thereof.

9. The method of claim 1, wherein the lipid bilayer comprises a mixture of (1) egg PC, and (2) 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC).

10. The method of claim 9, wherein the molar concentration of egg PC in the mixture is between about 40% to about 60% of the lipid bilayer.

11. The method of claim 9, wherein the molar concentration of DMPC is between about 40% to about 60% of the lipid bilayer.

12. The method of claim 1, wherein the lipid bilayer further comprises phospholipid selected from the group consisting of monoacyl or diacylphosphoglyceride.

13. The method of claim 1, wherein the lipid bilayer further comprises one or more phospholipids selected from the group consisting of PEG-poly(ethylene glycol)-derivatized distearoylphosphatidylethanolamine (PEG-DSPE), poly(ethylene glycol)-derivatized ceramides (PEG-CER), hydrogenated soy phosphatidylcholine (HSPC), egg phosphatidylcholine (EPC), phosphatidyl ethanolamine (PE), phosphatidyl glycerol (PG), phosphatidyl insitol (PI), monosialogangolioside, spingomyelin (SPM), distearoylphosphatidylcholine (DSPC), and dimyristoylphosphatidylglycerol (DMPG).

14. The method of claim 1, wherein the one or more anticancer agents are selected from the group consisting of doxorubicin, melphalan, bevacizumab, dactinomycin, cyclophosphamide, amifostine, etoposide, gemcitabine, altretamine, topotecan, a taxane, and a platinum based chemotherapeutic agent.

15. A method of treating a subject suffering from peritoneal cancer, the method comprising intraperitoneally administering to the subject a pharmaceutically effective amount of a nanocarrier composition, said nanocarrier composition comprising a plurality of porous silica nanoparticulates that: (a) are loaded with one or more pharmaceutically-active agents selected from the group consisting of doxorubicin, melphalan, bevacizumab, dactinomycin, cyclophosphamide, amifostine, etoposide, gemcitabine, altretamine, topotecan, a taxane or a platinum based chemotherapeutic agent, and (b) that are encapsulated by and that support a lipid bilayer comprising 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) to form a nanocarrier; wherein subsequent to administration, the lipid bilayer is disrupted in vivo upon contact with a reactive oxygen species (ROS) selected from the group consisting of ozone (O.sub.3), hydrogen peroxide, hypochlorite ion, hydroxyl radical, superoxide anion (O.sub.2.sup.-), and peroxynitrite.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.